Repligen Corporation (Nasdaq: RGEN) — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Interim financial statements are unaudited. Repligen develops and sells technologies and systems used in biopharmaceutical manufacturing.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $159.2 million | $207.6 million | $341.8 million | $414.0 million |
| Gross margin | 50.2% | 58.5% | 52.9% | 59.3% |
| Operating income | $19.4 million | $63.2 million | $50.7 million | $123.2 million |
| Net income | $20.1 million | $49.9 million | $48.9 million | $96.8 million |
| Diluted EPS | $0.35 | $0.88 | $0.86 | $1.68 |
| Operating cash flow | Not separately stated | Not separately stated | $45.6 million | $68.8 million |
Q2 revenue fell 23.3% year over year; first-half revenue declined 17.4%. Q2 operating margin was approximately 12.2% versus 30.4% a year earlier; net margin was approximately 12.6% versus 24.0%. First-half operating cash flow less purchases of property, plant and equipment and capitalized software was approximately $26.8 million.
At June 30, cash and cash equivalents were $603.7 million, versus $523.5 million at year-end 2022. Working capital was $625.0 million; current assets were $998.6 million and current liabilities $373.6 million. Convertible notes had a $285.5 million net carrying value and are classified as current. The company reported no other borrowings in the balance sheet presented.
Changes and drivers
- Management attributed lower sales chiefly to reduced COVID-19-related demand and customers using inventory previously purchased for COVID-19 therapeutics and vaccines, particularly affecting filtration products. Foreign exchange also weighed on revenue.
- Chromatography and Process Analytics performed strongly, including large-scale OPUS columns, chromatography systems and flowpaths, and slope spectroscopy products and services. Price increases partly offset declines.
- Gross margin contracted primarily on lower sales and production volumes, product mix (including weaker higher-margin consumables), added capacity and depreciation costs, and freight and raw-material inflation.
- Investment income rose to $6.0 million in Q2 and $11.5 million for the half, reflecting higher rates and invested cash balances. Contingent-consideration remeasurement was a $1.8 million Q2 expense, compared with a $6.9 million benefit in Q2 2022, affecting year-over-year operating-profit comparisons.
Cash, acquisition, outlook and risks
- First-half operating cash flow declined year over year to $45.6 million, including cash use from lower accrued liabilities, chiefly employee bonus payments, and higher prepaid expenses. Investing cash flow was positive $55.4 million largely because $102.3 million of Treasury bills matured; the company spent $28.1 million net of cash acquired on FlexBiosys and approximately $18.8 million on capital expenditures and capitalized software.
- On April 17, 2023, Repligen acquired FlexBiosys, a maker of single-use bioprocessing products, for approximately $41.1 million in cash, stock and contingent consideration. The preliminary allocation included $12.6 million of identified intangible assets and $14.4 million of goodwill; purchase accounting was not final at quarter-end.
- No full-year revenue or earnings guidance is stated in the provided filing text. Management expected COVID-related, inflation and supply-chain effects to continue through a significant part of 2023; R&D spending to gradually increase in the remainder of the year; and operating expenses to increase as the business expands. Management said existing cash was adequate for at least 24 months from the filing date, absent acquisitions of additional products, candidates or intellectual property.
- In July 2023, the board authorized restructuring activities; the company expected approximately $6 million in severance-related charges in the second half of 2023.
- The 0.375% convertible notes mature July 15, 2024. Holders could convert in Q3 2023 under the note terms; the filing says only a nominal amount had been requested for conversion to date. Foreign-exchange movements are not hedged. The company cites risks including lower product demand, customer purchasing patterns, inflation, supply constraints, acquisition integration and financial-sector disruption. Less than $0.1 million was held in SVB deposit accounts at quarter-end.
- The company reported no legal proceedings it believed would have a material adverse effect. Purolite represented 11.5% of accounts receivable and other receivables at June 30, 2023; no customer accounted for 10% or more of revenue in the periods shown.
Investor verification points
- Track whether COVID-related inventory normalization stabilizes and whether growth in chromatography and Process Analytics offsets continued filtration weakness.
- Verify subsequent-quarter revenue, gross margin and operating cash conversion against the sharp first-half declines.
- Review the final FlexBiosys purchase-price allocation, integration performance and any earnout payments.
- Monitor execution and timing of the restructuring and the expected $6 million charge, along with planned R&D and capacity spending.
- Assess the convertible notes’ conversion and 2024 maturity implications, and the company’s liquidity under potential acquisitions or weaker demand.